NE YORK, December 9, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG), Mylan Inc. (NASDAQ: MYL), St. Jude Medical, Inc. (NYSE: STJ), and Cigna Corporation (NYSE: CI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
UnitedHealth Group Inc. Research Report
On December 4, 2013, UnitedHealth Group Inc.'s (UnitedHealth Group) stock declined 0.11%, ending the day at $73.65. Over the previous three trading sessions, shares of UnitedHealth Group declined 1.11% compared to the S&P 500 which declined 0.72% during the same period. The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Celgene Corporation Research Report
On December 4, 2013, Celgene Corporation's (Celgene) stock rose 0.09%, ending the day at $160.07. Over the previous three trading sessions, shares of Celgene declined 1.05% compared to the Nasdaq Composite which declined 0.54% during the same period. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Mylan Inc. Research Report
On December 4, 2013, Mylan Inc. (Mylan) announced that the Company has completed the acquisition of the Agila injectables businesses from Strides Arcolab Limited (Strides) for up to c.$1.8 billion, including $250 million in contingent consideration. Mylan informed that the final transaction terms have been restructured since the initial announcement of the acquisition to include provisions such as a hold back, or contingent consideration, of $250 million of the potential $1.8 billion total purchase price. Mylan informed that the total purchase price will be payable in whole or in part to Strides upon satisfaction of certain regulatory conditions, and an enhanced escrow arrangement to fund any potential regulatory remediation costs. Mylan added that commercial enhancements have taken place that will reduce Agila's historic, long-term reliance on a business-to-business model and increase value to Mylan, including regaining full commercialization rights for most of Agila's U.S. portfolio, both marketed and pipeline products, including all oncolytics, and regaining significant product rights in Canada, Australia, Brazil, Japan and South Korea. Mylan also announced that the Company's Board of Directors has scheduled its Annual Meeting of Shareholders on April 11, 2014. The Full Research Report on Mylan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
St. Jude Medical, Inc. Research Report
On December 4, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that it has initiated a clinical study to evaluate the combination of peripheral nerve field stimulation (PNfS) and spinal cord stimulation (SCS), aimed at determining whether the two therapies together offer more effective management of chronic low back pain and leg pain than SCS alone. The Company added that the first patient in the SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation) study was enrolled by Dr. Thomas Yearwood, who is an interventional pain physician at Comprehensive Pain & Rehabilitation in Pascagoula, Mississippi. Dr. Porter McRoberts, Interventional Pain Physician, Holy Cross Orthopedic Institute, Fort Lauderdale, Florida, said, "We often see patients who have had multiple back surgeries to alleviate their debilitating chronic pain. Ultimately, many of these surgeries fail, leaving patients to seek other options like neurostimulation therapy. Peripheral nerve field stimulation therapy, targeting local nerves near the painful area, combined with traditional spinal cord stimulation, targeting the central nervous system, has the potential to improve our ability to effectively manage patients with difficult-to-treat low back pain." The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Cigna Corporation Research Report
On December 2, 2013, Cigna Corporation (Cigna) announced that the founder of Pets for Vets, a non-profit organization that matches shelter pets to armed forces veterans and trains them to be companion animals, has won the Cigna GO YOU Award. According to the Company, Clarissa Black, founder of Pets for Vets, saw the positive effect a dog can have on veterans suffering from PTSD (Post-Traumatic Stress Disorder) and other conditions. Cigna reported that the said organization currently has 19 chapters in 17 states. Cigna informed that the GO YOU Award entitles Pets for Vets to a $50,000 grant from Cigna Foundation, the Company's philanthropic foundation. The Company added that Black intends to use the funding to form additional chapters in other states and to match more shelter pets to veterans. The Full Research Report on Cigna Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner